Clinical Trials Browser

Phase 1/2 × Leukemia, T-Cell × 90 days × Clear all

NCT07471789 2026-03-13

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma